These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 24163168)
21. Overview of vasopressin receptor antagonists in heart failure resulting in hospitalization. De Luca L; Orlandi C; Udelson JE; Fedele F; Gheorghiade M Am J Cardiol; 2005 Dec; 96(12A):24L-33L. PubMed ID: 16399090 [TBL] [Abstract][Full Text] [Related]
22. Vasopressin: a new target for the treatment of heart failure. Lee CR; Watkins ML; Patterson JH; Gattis W; O'connor CM; Gheorghiade M; Adams KF Am Heart J; 2003 Jul; 146(1):9-18. PubMed ID: 12851603 [TBL] [Abstract][Full Text] [Related]
23. Treatment of congestive heart failure: what's new? Shaughnessy AF Pa Med; 1995 Jul; 98(7):28-9. PubMed ID: 7567049 [No Abstract] [Full Text] [Related]
24. [Hyponatraemia, antagonists of the antidiuretic hormone and cardiac failure]. de Groote P Arch Mal Coeur Vaiss; 2006 Mar; 99(3):215-20. PubMed ID: 16618024 [TBL] [Abstract][Full Text] [Related]
29. Effects of novel vasopressin receptor antagonists on renal function and cardiac hypertrophy in rats with experimental congestive heart failure. Bishara B; Shiekh H; Karram T; Rubinstein I; Azzam ZS; Abu-Saleh N; Nitecki S; Winaver J; Hoffman A; Abassi ZA J Pharmacol Exp Ther; 2008 Aug; 326(2):414-22. PubMed ID: 18467593 [TBL] [Abstract][Full Text] [Related]
30. Treatment of congestive heart failure. Butson R J Small Anim Pract; 2003 Nov; 44(11):516. PubMed ID: 14635966 [No Abstract] [Full Text] [Related]
31. The critical link of hypervolemia and hyponatremia in heart failure and the potential role of arginine vasopressin antagonists. Ghali JK; Tam SW J Card Fail; 2010 May; 16(5):419-31. PubMed ID: 20447579 [TBL] [Abstract][Full Text] [Related]
32. [What is new in the medical management of acute heart failure?]. Meyer P; White M; Keller RF; Lerch R; Hullin R Rev Med Suisse; 2010 Jun; 6(252):1211-7. PubMed ID: 20614757 [TBL] [Abstract][Full Text] [Related]
33. Heart failure: Part I. First hospitalization and post-hospital care. Wilkes MS; Middlekauff H; Hoffman JR West J Med; 1999 May; 170(5):268-73. PubMed ID: 10379217 [No Abstract] [Full Text] [Related]
34. Experience of a vasopressin receptor antagonist, tolvaptan, under the unique indication in Japanese heart failure patients. Kinugawa K; Imamura T; Komuro I Clin Pharmacol Ther; 2013 Oct; 94(4):449-51. PubMed ID: 23872863 [No Abstract] [Full Text] [Related]
35. Novel neurohormonal antagonist strategies: vasopressin antagonism, anticytokine therapy, and endothelin antagonism in patients who have heart failure. Hedrich O; Finley J; Konstam MA; Udelson JE Heart Fail Clin; 2005 Apr; 1(1):103-27. PubMed ID: 17386838 [No Abstract] [Full Text] [Related]
36. [Vasopressin V2-receptor antagonist, tolvaptan, for treatment of heart failure]. Yamamura Y; Sato O; Fujiki H Nihon Rinsho; 2007 May; 65 Suppl 5():164-8. PubMed ID: 17571379 [No Abstract] [Full Text] [Related]
37. Guidelines abstracted from consensus recommendations for the management of chronic heart failure. J Am Geriatr Soc; 2000 Nov; 48(11):1521-4. PubMed ID: 11083336 [TBL] [Abstract][Full Text] [Related]
38. Nonglycoside inotropes in congestive heart failure. Are they beneficial or harmful? Chatterjee K; Wolfe CL; DeMarco T Cardiol Clin; 1994 Feb; 12(1):63-72. PubMed ID: 8181026 [TBL] [Abstract][Full Text] [Related]
39. Increased vasopressin 1A receptor expression in failing human hearts. Zhu W; Tilley DG; Myers VD; Tsai EJ; Feldman AM J Am Coll Cardiol; 2014 Feb; 63(4):375-6. PubMed ID: 24140674 [No Abstract] [Full Text] [Related]